文献速递神经骨肌MR

MR关节造影后脑内钆沉积的评估

Evaluation of Gadolinium Deposition in the Brain After MR Arthrography.
PubMed 文献 · AJR Am J Roentgenol · 2018-08-14

该回顾性研究纳入31例无钆暴露史、2006至2016年接受MR关节造影后行平扫脑MRI的患者,与年龄匹配的无钆暴露对照比较齿状核、苍白球、丘脑与中脑脚、脑桥的信号强度比值,各比值均无显著差异,未发现关节内钆给药与脑内可检测钆沉积相关。

要点

  • 关节内钆给药后脑MRI齿状核、苍白球、丘脑信号比值与无钆暴露对照无显著差异。
  • 研究纳入31例MR关节造影后行平扫脑MRI且无钆暴露史的患者。
  • 关节内钆给药为超说明书使用,原文强调需关注患者安全。

核心结论

  • MR关节造影关节内钆给药与脑内可检测的钆沉积无关联。

研究设计与样本

  • 经机构审查委员会批准的回顾性研究,纳入2006至2016年接受MR关节造影后行平扫脑MRI、无钆暴露史的患者31例。
  • 在T1加权序列上手动放置双侧齿状核、双侧苍白球、双侧丘脑、双侧中脑脚和脑桥中央的感兴趣区,左右平均后计算信号强度比值。
  • 对年龄匹配、有脑MRI史但无钆暴露的对照者放置相似感兴趣区并计算比值,采用t检验比较患者与对照的信号强度比值。

诊断标准与关键数值

  • 患者与对照的齿状核/中脑脚信号强度比值比较p=0.40,无显著差异。
  • 患者与对照的齿状核/脑桥中央信号强度比值比较p=0.76,无显著差异。
  • 患者与对照的苍白球/中脑脚信号强度比值比较p=0.51,无显著差异。
  • 患者与对照的苍白球/脑桥中央信号强度比值比较p=0.86,无显著差异。
  • 患者与对照的丘脑/中脑脚信号强度比值比较p=0.93,无显著差异;丘脑/脑桥中央信号强度比值比较p=0.30,无显著差异。

临床应用与阅片要点

  • 原文指出关节内钆给药虽体积小但为超说明书使用,需仔细审查以保障患者安全。
  • 作者结论为MR关节造影关节内钆给药与脑内可检测钆沉积无关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Although significant investigation has been done into the deposition of gadolinium in the brains of patients receiving IV gadolinium, there is little research concerning nonintravenous uses of gadolinium, specifically in conjunction with musculoskeletal MR arthrography. Although small in volume, intraarticular administration is an off-label use of gadolinium, necessitating careful scrutiny for patient safety. Thus, we investigated the relationship between intraarticular gadolinium administration during MR arthrography and the presence of intracranial gadolinium deposition on subsequent brain MRI.

MATERIALS AND METHODS: An institutional review board-approved retrospective study was performed of patients with no history of gadolinium exposure who underwent MR arthrography from 2006 to 2016 followed by an unenhanced brain MRI examination. ROIs were manually placed within bilateral dentate nuclei (DN), bilateral globus pallidi (GP), bilateral thalami, bilateral middle cerebral peduncles (MCP), and the central pons (CP) on T1-weighted sequences. The left and right ROIs were averaged, and ratios of signal intensity were calculated for DN/MCP, DN/CP, GP/MCP, GP/CP, thalamus/MCP, and thalamus/CP. Similar ROIs were placed and ratios calculated for age-matched control subjects who had a history of brain MRI but no prior gadolinium exposure. We used t testing to compare signal intensity ratios between patients and control subjects.

RESULTS: A total of 31 patients met the inclusion criteria. We found no significant difference in signal intensity between patients and control subjects for DN/MCP (p = 0.40), DN/CP (p = 0.76), GP/MCP (p = 0.51), GP/CP (p = 0.86), thalamus/MCP (p = 0.93), and thalamus/CP (p = 0.30).

CONCLUSION: No association was found between intraarticular gadolinium administration for MR arthrography and detectable gadolinium deposition within the brain.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Kralik SF, Singhal KK, Frank MS, et al. Evaluation of Gadolinium Deposition in the Brain After MR Arthrography. AJR Am J Roentgenol. 2018. PMID: 30106613. doi:10.2214/AJR.18.19833

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。